
Please try another search
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Per Anders Göte Samuelsson | 63 | 2012 | Independent Director |
Per Wold-Olsen | 77 | 2018 | Independent Chairman of the Board |
Axel Gaston Glasmacher | 65 | - | Member of Clinical Advisory Board |
Jennifer Jackson | 72 | 2018 | Independent Director |
Brian M. Stuglik | 66 | 2018 | Independent Director |
Christian Jacques | 69 | 2018 | Member of Clinical Advisory Board |
Paul G. Richardson | - | - | Member of Clinical Advisory Board |
Christine Rankin | - | 2025 | Director |
Lori Anne Kunkel | 67 | - | Member of Clinical Advisory Board |
Cecilia Daun Wennborg | 62 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review